MedTrace Logo

The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS)

NCT00409721 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2011-03-02

No results posted yet for this study

Summary

The purpose of the study is to investigate the effects of memantine in ALS patients using functional outcome measures.

Conditions

Interventions

DRUG

Memantine

Sponsors & Collaborators

  • ALS Association

    collaborator OTHER

  • University of Alberta

    lead OTHER

Principal Investigators

  • Ming Chan, MD · University of Alberta

  • Sanjay Kalra, MD · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00409721 on ClinicalTrials.gov